0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover281.86%IV-42.46%PremiumJan 17, 2025Expiry Date7.38Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9064Delta0.0183Gamma2.20Leverage Ratio-0.0611Theta0.0027Rho1.99Eff Leverage0.0054Vega
Rigel Pharmaceuticals Stock Discussion
whoa! some Dip
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Let's break 30.+
27.+
No comment yet